Soluclinipharm private limited

The medicine can only be obtained with a prescription and treatment with Caprelsa should be started and supervised by a doctor who has experience of treating medullary thyroid cancer, of using cancer medicines and of assessing electrocardiograms (ECG, a test that measures the electrical activity of the heart). Patients must be given a patient alert card containing important safety information and they must be informed by their doctor about the risks of Caprelsa.

Caprelsa is available as tablets (100 mg and 300 mg) and the recommended dose for adults is 300 mg once a day, taken at around the same time each day. The dose for children aged 5 years or older is calculated using the child’s weight and height. Patients who cannot swallow tablets can mix the tablet in plain (non-sparkling) water.

The doctor may temporarily stop Caprelsa treatment and reduce the dose if the patient has abnormal ECG or severe side effects. Treatment is continued for as long as the patient benefits from it.

Caprelsa may work less well in patients without a mutation (change) in a gene called the ‘rearranged during transfection’ (RET) gene. It is recommended that the doctor checks for RET mutation at the start of Caprelsa treatment.